BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma

Purpose: MYC-amplified medulloblastomas are highly lethal tumors. Bromodomain and extraterminal (BET) bromodomain inhibition has recently been shown to suppress MYC-associated transcriptional activity in other cancers. The compound JQ1 inhibits BET bromodomain-containing proteins, including BRD4. Here, we investigate BET bromodomain targeting for the treatment of MYC-amplified medulloblastoma. Experimental Design: We evaluated the effects of genetic and pharmacologic inhibition of BET bromodomains on proliferation, cell cycle, and apoptosis in established and newly generated patient- and genetically engineered mouse model (GEMM)-derived medulloblastoma cell lines and xenografts that harbored amplifications of MYC or MYCN. We also assessed the effect of JQ1 on MYC expression and global MYC-associated transcriptional activity. We assessed the in vivo efficacy of JQ1 in orthotopic xenografts established in immunocompromised mice. Results: Treatment of MYC-amplified medulloblastoma cells with JQ1 decreased cell viability associated with arrest at G1 and apoptosis. We observed downregulation of MYC expression and confirmed the inhibition of MYC-associated transcriptional targets. The exogenous expression of MYC from a retroviral promoter reduced the effect of JQ1 on cell viability, suggesting that attenuated levels of MYC contribute to the functional effects of JQ1. JQ1 significantly prolonged the survival of orthotopic xenograft models of MYC-amplified medulloblastoma (P < 0.001). Xenografts harvested from mice after five doses of JQ1 had reduced the expression of MYC mRNA and a reduced proliferative index. Conclusion: JQ1 suppresses MYC expression and MYC-associated transcriptional activity in medulloblastomas, resulting in an overall decrease in medulloblastoma cell viability. These preclinical findings highlight the promise of BET bromodomain inhibitors as novel agents for MYC-amplified medulloblastoma. Clin Cancer Res; 20(4); 912–25. ©2013 AACR.

[1]  Karl-Frédéric Vieux,et al.  Noncanonical Regulation of the Hedgehog Mediator GLI1 by c-MYC in Burkitt Lymphoma , 2013, Molecular Cancer Research.

[2]  K. Stegmaier,et al.  Targeting MYCN in neuroblastoma by BET bromodomain inhibition. , 2013, Cancer discovery.

[3]  David T. W. Jones,et al.  The Role of Chromatin Remodeling in Medulloblastoma , 2013, Brain pathology.

[4]  J. Mesirov,et al.  Integrated Genomic Analysis of the 8q24 Amplification in Endometrial Cancers Identifies ATAD2 as Essential to MYC-Dependent Cancers , 2013, PloS one.

[5]  T. Zhou,et al.  Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children's Oncology Group trial A9961. , 2013, Neuro-oncology.

[6]  Steven J. M. Jones,et al.  Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma , 2013, Acta Neuropathologica.

[7]  J. Bradner,et al.  Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia (AML) , 2012, Oncotarget.

[8]  Stefan Knapp,et al.  The bromodomain interaction module , 2012, FEBS letters.

[9]  Steven J. M. Jones,et al.  Subgroup-specific structural variation across 1,000 medulloblastoma genomes , 2012, Nature.

[10]  David T. W. Jones,et al.  K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas , 2012, Acta Neuropathologica.

[11]  P. Northcott,et al.  Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC. , 2012, Cancer cell.

[12]  A. McKenna,et al.  Absolute quantification of somatic DNA alterations in human cancer , 2012, Nature Biotechnology.

[13]  A. Gingras,et al.  Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family , 2012, Cell.

[14]  J. Steen,et al.  Pleiotropic effects of miR-183~96~182 converge to regulate cell survival, proliferation and migration in medulloblastoma , 2012, Acta Neuropathologica.

[15]  Scott L. Pomeroy,et al.  Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas , 2012, Acta Neuropathologica.

[16]  P. Febbo,et al.  An animal model of MYC-driven medulloblastoma. , 2012, Cancer cell.

[17]  David T. W. Jones,et al.  Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma , 2012, Nature.

[18]  C. Sander,et al.  Mutual exclusivity analysis identifies oncogenic network modules. , 2012, Genome research.

[19]  Li Ding,et al.  Somatic Histone H3 Alterations in Paediatric Diffuse Intrinsic Pontine Gliomas and Non-Brainstem Glioblastomas , 2012, Nature Genetics.

[20]  Scott L. Pomeroy,et al.  Molecular subgroups of medulloblastoma: the current consensus , 2011, Acta Neuropathologica.

[21]  R. Young,et al.  BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.

[22]  C. Wetmore,et al.  Sequential activation of Snail1 and N-Myc modulates sonic hedgehog-induced transformation of neural cells. , 2011, Cancer research.

[23]  P. Sorensen,et al.  Abstract 5336: Macrophage migration inhibitory factor (MIF) plays roles in proliferation, survival and migration of Ewing tumor cells through the activation of several tyrosine kinases , 2011 .

[24]  J. Mesirov,et al.  Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Hendrik Witt,et al.  Medulloblastoma comprises four distinct molecular variants. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  D. Frappaz,et al.  Brain tumors: from childhood through adolescence into adulthood. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  David Haussler,et al.  Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM , 2010, Bioinform..

[28]  S. Vandenberg,et al.  Pleiotropic role for MYCN in medulloblastoma. , 2010, Genes & development.

[29]  Eli Upfal,et al.  Algorithms for Detecting Significantly Mutated Pathways in Cancer , 2010, RECOMB.

[30]  Derek Y. Chiang,et al.  The landscape of somatic copy-number alteration across human cancers , 2010, Nature.

[31]  Joshua M. Korn,et al.  Integrated genotype calling and association analysis of SNPs, common copy number polymorphisms and rare CNVs , 2008, Nature Genetics.

[32]  Dirk Troost,et al.  Integrated Genomics Identifies Five Medulloblastoma Subtypes with Distinct Genetic Profiles, Pathway Signatures and Clinicopathological Features , 2008, PloS one.

[33]  E. S. Venkatraman,et al.  A faster circular binary segmentation algorithm for the analysis of array CGH data , 2007, Bioinform..

[34]  P. Burger,et al.  Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Jill P. Mesirov,et al.  Comparative gene marker selection suite , 2006, Bioinform..

[36]  T. Curran,et al.  Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[38]  R. Mulhern,et al.  Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  M. Wigler,et al.  Circular binary segmentation for the analysis of array-based DNA copy number data. , 2004, Biostatistics.

[40]  M. Hofker.  Faculty Opinions recommendation of PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. , 2003 .

[41]  M. Daly,et al.  PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.

[42]  Robert J. Wechsler-Reya,et al.  Transcriptional profiling of the Sonic hedgehog response: A critical role for N-myc in proliferation of neuronal precursors , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[43]  Terence P. Speed,et al.  A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..

[44]  Michael D. Cole,et al.  Nmyc upregulation by sonic hedgehog signaling promotes proliferation in developing cerebellar granule neuron precursors , 2003, Development.

[45]  R. McLendon,et al.  Comprehensive molecular cytogenetic investigation of chromosomal abnormalities in human medulloblastoma cell lines and xenograft. , 2002, Neuro-oncology.

[46]  Cheng Li,et al.  Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application , 2001, Genome Biology.

[47]  C. Li,et al.  Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[48]  J. Trojanowski,et al.  Establishment and Characterization of the Human Medulloblastoma Cell Line and Transplantable Xenograft D283 Med , 1985, Journal of neuropathology and experimental neurology.